StartHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Seneste lukkekurs
25,85 €
Dagsinterval
25,67 € - 25,67 €
Årsinterval
19,52 € - 36,69 €
Markedsværdi
3,58 mia. USD
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | mar. 2024info | År til år-ændring |
---|---|---|
Indtægt | — | — |
Driftsudgifter | 126,19 mio. | 28,63 % |
Nettoindtægt | -125,30 mio. | -357,42 % |
Overskudsgrad | — | — |
Earnings per share | -1,02 | -326,67 % |
EBITDA | -121,67 mio. | -339,34 % |
Effektiv afgiftssats | — | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | mar. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 520,91 mio. | 8,30 % |
Samlede aktiver | 955,15 mio. | 7,16 % |
Samlede passiver | 459,74 mio. | 7,87 % |
Samlet egenkapital | 495,40 mio. | — |
Shares outstanding | 124,20 mio. | — |
Kurs/indre værdi | 6,63 | — |
Afkast af aktiver | -39,90 % | — |
Afkast af kapital | -43,18 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | mar. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | -125,30 mio. | -357,42 % |
Pengestrøm fra drift | -92,38 mio. | -191,68 % |
Pengestrøm fra investering | -268,94 mio. | -645,70 % |
Pengestrøm fra finansiering | 430,78 mio. | 82.741,73 % |
Nettoændring i likviditet | 69,49 mio. | 203,27 % |
Fri pengestrøm | -91,82 mio. | -262,49 % |
Om
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Administrerende direktør
Grundlagt
1. jan. 2004
Hovedkvarter
Website
Ansatte
525